Mokdong Himchan Hospital Macorobot Artificial Joint Surgery surpasses 10,000 cases, CEO Lee Soo-chan "Patient Satisfaction is high"
Aug 01, 2024
Mokdong Himchan Hospital has recently surpassed 10,000 cases of Mako robot artificial joint surgery, drawing attention for its abundant clinical experience and success rate in the field of robot artificial joint surgery.
Artificial joint surgery is a treatment for end-stage degenerative arthritis, and since it began in the late 1970s in Korea, it has been constantly developing by combining various technologies such as navigation, minimal incision, and biosensor. Recently, robots have been introduced to increase accuracy and safety, increasing the success rate of surgery and satisfaction of patients.
Artificial joint surgical robots mainly used in Korea include Striker's Mako, Zimmer Biomet's Rosa, Smith & Nephew's Navio, and Cubis Joint of Curexo. According to Korea Striker (CEO Shim Hyun-woo), Mako's Korean branch, Mako Robot's domestic surgery accounted for about 61% of the total number of robot artificial joint surgeries performed in Korea as of 2023, which also has a high domestic share.
Mokdong Himchan Hospital is said to have led the generalization of Mako robot artificial joint surgery in Korea by surpassing 10,000 cases in about four years since it first introduced the Mako robot system in June 2020.
Shim Hyun-woo, CEO of the Korea Striker, said "The number of Makorobot artificial joint surgery (pre-replacement and semi-replacement) in 2023 at Mokdong Himchan Hospital is more than 2,700, and a single hospital performed the most Makorobot surgery in the world last year."
According to the Korea Striker, Makorobot is approved by the U.S. Food and Drug Administration (FDA) for total knee arthroplasty, partial arthroplasty, and total hip arthroplasty, and more than 2,000 units are currently in operation worldwide. It also has more than 1 million clinical cases and 425 research results.
Makorobot artificial joint surgery is characterized by high satisfaction not only for patients but also for doctors performing surgery. According to a survey of 24 orthopedic surgeons at Himchan Hospital, they were satisfied with the accuracy of surgery (32%), ligament balance and leg axis (24%), preoperative planning (23%), small bleeding and rapid recovery (21%), and all respondents answered that they would like to actively recommend robotic artificial joint surgery to their fellow doctors.
The biggest advantage of Makorobot's artificial joint surgery is that the amount of bleeding is small. In conventional surgery, the axis of the leg is adjusted by drilling a long hole in the thigh bone and inserting a device, and bleeding follows in the process. On the other hand, robots can reduce bleeding because they attach sensors without drilling holes.
Lee Soo-chan, CEO of Himchan Hospital (Orthopedic surgeon), said "In the past, there were cases where two to three cases a year were transferred to high-level general hospitals due to general functional decline, delirium, and severe hypotension due to bleeding, but there are few cases when performing robotic surgery." According to a survey conducted by Himchan Hospital's Arthology Research Institute, the amount of bleeding in robotic surgery decreased by 36% compared to general surgery. If the amount of bleeding is small, various complications, side effects, and the risk of infection due to additional blood transfusions are lowered, and elderly patients can also undergo surgery safely due to rapid recovery.
Lee Soo-chan, president of the company, said "The robotic surgery has reduced the duration of pain and recovery, further increasing the satisfaction of patients." In particular, even though only the inside of the cartilage is worn out and the magnetic joint can be preserved, robots are also applied to partial replacement surgery, which is difficult to operate. As a result of performing robotic surgery over the past four years, we have verified the success rate of surgery through numerous clinical trials, so we plan to introduce and actively utilize robots in hip artificial joint surgery."
Meanwhile, a research team at the Institute of Arthroscopic Medicine at Himchan Hospital has published a total of five international papers on macorobots so far, and two of them have been published in SCIE-level international prominent journals. As of July 2024, a total of seven papers on macorobots have been published by domestic medical staff, and five of them have been published by Himchan Hospital, which is considered a remarkable achievement.
Artificial joint surgery is a treatment for end-stage degenerative arthritis, and since it began in the late 1970s in Korea, it has been constantly developing by combining various technologies such as navigation, minimal incision, and biosensor. Recently, robots have been introduced to increase accuracy and safety, increasing the success rate of surgery and satisfaction of patients.
Artificial joint surgical robots mainly used in Korea include Striker's Mako, Zimmer Biomet's Rosa, Smith & Nephew's Navio, and Cubis Joint of Curexo. According to Korea Striker (CEO Shim Hyun-woo), Mako's Korean branch, Mako Robot's domestic surgery accounted for about 61% of the total number of robot artificial joint surgeries performed in Korea as of 2023, which also has a high domestic share.
Mokdong Himchan Hospital is said to have led the generalization of Mako robot artificial joint surgery in Korea by surpassing 10,000 cases in about four years since it first introduced the Mako robot system in June 2020.
Shim Hyun-woo, CEO of the Korea Striker, said "The number of Makorobot artificial joint surgery (pre-replacement and semi-replacement) in 2023 at Mokdong Himchan Hospital is more than 2,700, and a single hospital performed the most Makorobot surgery in the world last year."
According to the Korea Striker, Makorobot is approved by the U.S. Food and Drug Administration (FDA) for total knee arthroplasty, partial arthroplasty, and total hip arthroplasty, and more than 2,000 units are currently in operation worldwide. It also has more than 1 million clinical cases and 425 research results.
Makorobot artificial joint surgery is characterized by high satisfaction not only for patients but also for doctors performing surgery. According to a survey of 24 orthopedic surgeons at Himchan Hospital, they were satisfied with the accuracy of surgery (32%), ligament balance and leg axis (24%), preoperative planning (23%), small bleeding and rapid recovery (21%), and all respondents answered that they would like to actively recommend robotic artificial joint surgery to their fellow doctors.
The biggest advantage of Makorobot's artificial joint surgery is that the amount of bleeding is small. In conventional surgery, the axis of the leg is adjusted by drilling a long hole in the thigh bone and inserting a device, and bleeding follows in the process. On the other hand, robots can reduce bleeding because they attach sensors without drilling holes.
Lee Soo-chan, CEO of Himchan Hospital (Orthopedic surgeon), said "In the past, there were cases where two to three cases a year were transferred to high-level general hospitals due to general functional decline, delirium, and severe hypotension due to bleeding, but there are few cases when performing robotic surgery." According to a survey conducted by Himchan Hospital's Arthology Research Institute, the amount of bleeding in robotic surgery decreased by 36% compared to general surgery. If the amount of bleeding is small, various complications, side effects, and the risk of infection due to additional blood transfusions are lowered, and elderly patients can also undergo surgery safely due to rapid recovery.
Lee Soo-chan, president of the company, said "The robotic surgery has reduced the duration of pain and recovery, further increasing the satisfaction of patients." In particular, even though only the inside of the cartilage is worn out and the magnetic joint can be preserved, robots are also applied to partial replacement surgery, which is difficult to operate. As a result of performing robotic surgery over the past four years, we have verified the success rate of surgery through numerous clinical trials, so we plan to introduce and actively utilize robots in hip artificial joint surgery."
Meanwhile, a research team at the Institute of Arthroscopic Medicine at Himchan Hospital has published a total of five international papers on macorobots so far, and two of them have been published in SCIE-level international prominent journals. As of July 2024, a total of seven papers on macorobots have been published by domestic medical staff, and five of them have been published by Himchan Hospital, which is considered a remarkable achievement.
|
bellho@sportschosun.com
